Can immune antibodies fight toxic shock in kids? small trial hopes to find out
NCT ID NCT02219165
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether giving intravenous immunoglobulin (IVIG) to children with toxic shock syndrome is practical and might help. Toxic shock is a rare but life-threatening reaction to bacterial toxins. The trial enrolled 30 children in intensive care, giving them either IVIG or a placebo (albumin) within 12 hours of shock. The main goal was to see if such a study could be done smoothly, not to prove IVIG works. Researchers also tracked organ failure and side effects to guide a future larger trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Intravenous immunoglobulin (IVIG)
- What this could lead to
- If this pilot shows IVIG is feasible and reduces organ failure, it could lead to a larger trial testing whether IVIG can save more children from toxic shock.
- What could go wrong
- This is a small pilot study (30 children) focused on feasibility, not on proving that IVIG works. The treatment is expensive and not yet approved for toxic shock, so results may not lead to a proven therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NECROTIZING FASCIITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Femme Mère Enfant
Bron, 69677, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.